Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹580 Cr
verified against source
Revenue YoY
10.9%
reported change
EBITDA
₹62.6 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
IOL Chemicals reported Q3 FY26 revenue of ₹580 crore (+10.9% YoY) and EBITDA of ₹62.6 crore (+22.8% YoY), with EBITDA margin expanding 100 bps to 10.7%. Pharma segment contributed 61% of revenue, driven by ibuprofen (64% of pharma) and non-ibuprofen APIs (36%). Chemicals ran at near 100% capacity. Management guided for ₹600 crore revenue in Q4 and 10-15% top-line growth in FY27, with EBITDA margin improvement of 1-2% in Q4. However, elevated fuel costs (rice husk) and paracetamol underutilization (60% capacity) pressured margins. The company targets a 50/50 revenue mix between ibuprofen and non-ibuprofen APIs over two years. Key risk: sustained high fuel costs could delay margin recovery.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects to achieve ₹600 crore revenue in Q4 FY26, up from ₹580 crore in Q3.
- Management guided for 10-15% top-line growth in FY27, driven by pharma and chemicals.
- Management expects 15-20% growth in profit after tax for FY27.
- Management expects EBITDA margin to increase by 1-2% in Q4 FY26 compared to Q3.
Risks flagged
- Rice husk prices remain elevated due to off-season and high demand, impacting power and fuel costs and margin recovery.
- Paracetamol capacity utilization at 60% and pricing pressure are dragging pharma margins; management acknowledged focusing on volume over price.
- Analyst raised concerns about new entrants and technological advantages; management downplayed but noted global capacity closures.
- Management previously guided for 13-14% EBITDA margin in H2 but now expects 11-12%, citing fuel cost headwinds.
Key quotes
- Our IU plant is running around 90 to 95% capacity utilization and we are not facing any problem which you have mentioned that uh any surplus but our capacity utilization is continue at above 90 to 95%.
- We expect minimum 10 to 15% uh growth in the top line and uh 15 to 20% in the bottom line.
- We are not able to achieve the target uh because of unexpected rise in the fuel cost. So now we hope we will do better in the uh coming quarter.
Research modules